BPS - Advance the Development of V920, a Vaccine Against Ebola Virus Using a Recombinant Vesicular Stomatitis Virus Vector. Igf::ot::igf
Contract Overview
Contract Amount: $65,103,309 ($65.1M)
Contractor: Merck Sharp & Dohme LLC
Awarding Agency: Department of Health and Human Services
Start Date: 2016-08-29
End Date: 2024-09-30
Contract Duration: 2,954 days
Daily Burn Rate: $22.0K/day
Official Description: BPS - ADVANCE THE DEVELOPMENT OF V920, A VACCINE AGAINST EBOLA VIRUS USING A RECOMBINANT VESICULAR STOMATITIS VIRUS VECTOR. IGF::OT::IGF
Place of Performance
Location: Iowa, 50010
State: Iowa Government Spending